No previous suggestions found.

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

1
Home
Companies

CTI BioPharma

#5037

Rank

$661.82M

Marketcap

US United States

Country

CTI BioPharma
Leadership team

Dr. Adam R. Craig M.B.A., M.D., Ph.D. (Pres, CEO, Interim Chief Medical Officer & Director)

Mr. David H. Kirske (Exec. VP, CFO & Sec.)

Mr. Ed Bell (Sr. Director of Investor Relations)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Headquarters
Seattle, Washington, United States
Established
1991
Company Registration
SEC CIK number: 0000891293
Revenue
20M - 100M
Traded as
CTIC
Social Media
URL
https://www.ctibiopharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
History

Founded in 1991, CTI BioPharma based in Seattle, Wash., is a commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers.

Mission
CTI BioPharma's mission is to develop targeted therapies that provide meaningful changes in patients' lives.
Vision
CTI BioPharma's vision is to become a leading provider of novel targeted therapies that meet the demands of healthcare providers and patients.
Key Team

Mr. James K. Fong (Exec. VP & Chief Commercial Officer)

Mr. Bruce K. Bennett Jr. (Sr. VP Global Pharmaceutical Operations)

Mr. John P. Volpone (Exec. VP & Chief of Staff)

Dr. Jennifer A. Smith (Sr. VP of Biometrics)

Recognition and Awards
CTI BioPharma has been recognized with a number of awards throughout its history, including the Washington Biotechnology & Biomedical Association's Pioneer of the Year award , the Fred Hutchinson Cancer Research Center's Visionary Award , and the American Cancer Society's Horizon Award .
References

https://in.investing.com/equities/cell-therapeutics

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/cell-therapeutics

https://finance.yahoo.com/quote/CTIC/

https://www.ctibiopharma.com

https://sec.report/CIK/0000891293

CTI BioPharma
Leadership team

Dr. Adam R. Craig M.B.A., M.D., Ph.D. (Pres, CEO, Interim Chief Medical Officer & Director)

Mr. David H. Kirske (Exec. VP, CFO & Sec.)

Mr. Ed Bell (Sr. Director of Investor Relations)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Headquarters
Seattle, Washington, United States
Established
1991
Company Registration
SEC CIK number: 0000891293
Revenue
20M - 100M
Traded as
CTIC
Social Media
URL
https://www.ctibiopharma.com
About

Businessabc provides a digital business directory, resources, a marketplace, and a digital blockchain AI certification for businesses, organisations, and professionals.

contacts

businessabc@ztudium.com

Follow Us
Produced by
In collaboration with
Logo

Copyright 2024 © Businessabc powered by ztudium

Privacy Policy